Company intelligence / Profile preview

Novalyst Discovery

Illkirch-Graffenstaden, Grand Est, France

Ownership: Private
Development stage: Other

Overview

Novalyst Discovery was a French contract research organization (CRO) that provided specialized medicinal chemistry and chemical synthesis services to the global life sciences sector. Established in 2002 and headquartered in Illkirch, France, the company focused on accelerating drug discovery through custom synthesis, lead optimization, and the development of innovative chemical libraries. Novalyst was recognized for its expertise in complex molecular assembly and process research and development. In 2009, the company was acquired by OmegaChem, a Canadian-based CRO, to strengthen its international service portfolio. Following subsequent industry consolidations, the legacy of Novalyst Discovery is now part of Sygnature Discovery.

Modalities: Small molecule
Industry: Drug Discovery Services

Beyond the preview

Go deeper on Novalyst Discovery.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Novalyst Discovery.

Explore the full profile